Brief: Biocryst Pharmaceuticals Says CFO Anthony Doyle To Resign Effective April 9, 2025
04/03/2025 14:11
March 4 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O: BIOCRYST PHARMACEUTICALS INC - CFO ANTHONY DOYLE TO RESIGN EFFECTIVE APRIL 9, 2025 Source text: [ID:n0001171843-25-001231] Further company coverage: BCRX.O (Reuters.Briefs@thomsonreuters.com)
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026